What happens when breakthrough drugs collide with outdated systems of access?

In this episode, Ipsos' Kiran Khepar and Neil Grubert, Global Market Access Consultant, explore the friction between innovation and access, and what it means for the future of healthcare systems.

GLP-1 therapies are redefining what’s possible in obesity treatment, but reimbursement pathways haven’t caught up. From out-of-pocket models to public payer resistance, we’re unpacking how market dynamics are shaping who really gets treated and who’s left behind.

Obesity isn't just a number on a scale – it's a complex, chronic condition that demands long-term, system-wide change.

In this episode, Ipsos' Melissa Moodley and Anthony Cunliffe, Macmillan National Lead Medical Adviser, dive into what the UK Government’s 10-Year Plan for Health means for primary care, how we can reshape obesity care at the frontline, and what it takes to build a health service fit for the future.

From early intervention and stigma reduction to team-based models and real-world evidence, this episode brings the policy to life through practical insights.

Listen to Ipsos' Brooke Ramsdale and Sarah Le Brocq, Director, All About Obesity, discuss the lived realities of people with obesity, offering real-world insights into how they navigate the evolving treatment landscape. They explore the everyday challenges encounter in accessing comprehensive care and confronting societal perceptions, alongside aspirations for a future where obesity is understood and treated with empathy, equity, and genuine innovation.

Listen to Thomas Fife-Schaw and Nick Gabery Adams, former VP of Corporate Brand at Novo Nordisk, discuss how GLP-1 medications like Ozempic and Wegovy are changing the pharmaceutical landscape. From reshaping corporate reputation, to boosting investor confidence, discover how these drugs are rewriting the rules for pharma brands.

Over a billion people globally are living with obesity, but its status as a ‘disease’ and available solutions have often been contentious.

When the market for obesity drugs is projected to hit $100 billion by 2030, what will be the impact for patients, payers, healthcare professionals, and industries beyond healthcare?

Listen to Melissa Moodley and Dr. Stuart W. Flint, Associate Professor at the University of Leeds, as they explore some of the trends and latest views on obesity treatment, such as the onus on patients to manage their own obesity, the possibility of preventative care, government focus and the effect of celebrity on GLP-1 uptake.

Keiran, Holly and Cameron take you through our latest polls, discussing the US Election, Kemi Badenoch's first ratings, how Starmer is polling and Reform UK.

00:00- Intro

00:55 - The US Election & British politics

07:03 - Kemi Badenoch

13:00 - Keir Starmer & the Budget

18:49 - Reform UK and Farage

#Budget #RachelReeves #keirstarmer #labourparty #conservativeparty #polling #toryleadership #ukpolitics #taxes #generalelection2024 #ukparliament #parliament #westminster #whitehall #unitedkingdom #Farage #Reform #USAElection2024

Keiran and Holly are joined by Stephen Bush, Associate Editor and Columnist at the Financial Times, and discuss our latest polls showing Starmer's unfavorability at an all-time high, why this might be happening and question, how much does this matter at this stage?

The trio also look ahead to the Labour Conference and speculate on what we might expect to see.

Subscribe to our YouTube channel to stay up to date with Politics Talk episodes and other Ipsos content. Listen to Ipsos UK Podcast: Politics Talk, wherever you get your podcasts - http://bit.ly/3jt1INd

+++

Keiran Pedley, UK Director of Politics, Public Affairs, Ipsos

@keiranpedley

Holly Day, Research Manager, UK Public Affairs, Ipsos

@HollyDay1993

Stephen Bush, Associate Editor and Columnist, The Financial Times

@stephenkb